Robledo ÁFH, Velasco VMA

Language: Spanish
References: 24
Page: 173-176
PDF size: 63.05 Kb.

Text Extraction

No abstract

REFERENCES

1. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 783-801.

2. Gay N, Gangloff M, Weber A. Toll-like receptors as molecular switches. Nat Rev Immunol 2006; 6: 693-8.

3. Rock F, Hardiman G, Timans J, Kastelein R, Bazan J. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci USA 1998; 95: 588-93.

4. Diebold S. Recognition of viral single-stranded RNA by Toll-like receptors. Adv Drug Deliv Rev 2008; 60: 813-23.

5. Gazzinelli R, Denkers E. Protozoan encounters with Toll-like receptor signalling pathways: implications for host parasitism. Nat Rev Immunol 2006; 6: 895-906.

6. Romagne F. Current and future drugs targeting one class of innate immunity receptors: the Toll-like receptors. Drug Discov Today 2007; 12: 80-7.

7. Gibson S, Lindh J, Riter T et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol 2002; 218: 74-86.

8. Harrison C, Miller R, Bernstein D. Post-therapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs. Antimicrob Agents Chemother 1994; 38: 2059-64.

9. Sparling J, Checketts S, Chapman M. Imiquimod for plantar and periungual warts. Cutis 2001; 68: 397-9.

10. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004; 50: 722-33.

11. Schulze H, Cribier B, Requena L et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol 2005; 152: 939-47.

12. Schön M, Bong A, Drewniok C et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 2003; 95: 1138-49.

13. Schön M, Wienrich B, Drewniok C et al. Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod. J Invest Dermatol 2004; 122: 1266-76.

14. Kerkelä E, Saarialho-Kere U. Matrix metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer. Exp Dermatol 2003; 12: 109-25.

15. Majewski S, Marczak M, Mlynarczyk B, Benninghoff B, Jablonska S. Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis. Int J Dermatol 2005; 44: 14-9.

16. Martinez-Piñeiro J. BCG vaccine in superficial bladder tumors: eight years later. Eur Urol 1984; 10: 93-100.

17. Kundi M. New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev Vaccines 2007; 6: 133-40.

18. Krieg A. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006; 5: 471-84.

19. Cooper C, Davis H, Morris M et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 2004; 24: 693-701.

20. Verthelyi D, Gursel M, Kenney R et al. CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection. J Immunol 2003; 170: 4717-23.

21. Garay R, Viens P, Bauer J et al. Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help. Eur J Pharmacol 2007; 563: 1-17.

22. Sato K, Saiki I, Yoo Y et al. DT-5461, a new synthetic lipid A analogue, inhibits lung and liver metastasis of tumor in mice. Jpn J Cancer Res 1992; 83: 1081-7.

23. Nakatsuka M, Kumazawa Y, Homma J, Kiso M, Hasegawa A. Inhibition in mice of experimental metastasis of B16 melanoma by the synthetic lipid A-subunit analogue GLA-60. Int J Immunopharmacol 1991; 13: 11-9.

24. Ulevitch R. Therapeutics targeting the innate immune system. Nat Rev Immunol 2004; 4: 512-20.